Discounts Help Prompt UK’s NICE Turnaround on Dupixent and Ocrevus

 
• By Francesca Bruce

After initially saying no, the UK health technology appraisal body, NICE, has recommended for use on the National Health Service Sanofi/Regeneron’s Dupixent and Roche’s Ocrevus. Confidential discounts helped convince NICE.

nerve cells, concept for neurodegenerative and neurological disease
Nerve signals between the brain and other parts of the body are disrupted by damage to the myelin and nerve fibers in patients with multiple sclerosis.

More from Health Technology Assessment

More from Market Access